SOST and bone disorder: Sclerostin and DKK1 antibodies are interesting as pharmacological options in osteoporosis treatment and other bone disorders [44], but sclerostin is a highly selective pathway modulator [34], possibly influencing bone formation, as well as bone resorption, thus making it a more suitable pharmacotherapeutic option.